Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of “Buy” by Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have earned an average rating of “Buy” from the thirteen research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, ten have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $49.91.

DYN has been the topic of a number of analyst reports. Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Chardan Capital reiterated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Royal Bank of Canada initiated coverage on Dyne Therapeutics in a report on Tuesday, November 26th. They set an “outperform” rating and a $45.00 price objective on the stock. Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Finally, StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th.

Insider Buying and Selling at Dyne Therapeutics

In other news, Director Dirk Kersten sold 23,671 shares of the stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total transaction of $836,769.85. Following the transaction, the director now directly owns 99,652 shares in the company, valued at approximately $3,522,698.20. This represents a 19.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jason P. Rhodes sold 782 shares of the firm’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $33.10, for a total value of $25,884.20. Following the transaction, the director now directly owns 15,962 shares in the company, valued at approximately $528,342.20. This represents a 4.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 44,742 shares of company stock worth $1,443,246 over the last three months. 20.77% of the stock is owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors have recently made changes to their positions in DYN. Bank of New York Mellon Corp lifted its stake in Dyne Therapeutics by 52.5% in the second quarter. Bank of New York Mellon Corp now owns 311,504 shares of the company’s stock worth $10,993,000 after purchasing an additional 107,233 shares during the last quarter. Lisanti Capital Growth LLC boosted its holdings in Dyne Therapeutics by 22.5% during the 2nd quarter. Lisanti Capital Growth LLC now owns 106,140 shares of the company’s stock valued at $3,746,000 after acquiring an additional 19,530 shares during the period. Privium Fund Management B.V. purchased a new stake in Dyne Therapeutics during the 2nd quarter valued at about $486,000. Rhumbline Advisers grew its position in Dyne Therapeutics by 23.7% during the 2nd quarter. Rhumbline Advisers now owns 121,595 shares of the company’s stock worth $4,291,000 after acquiring an additional 23,266 shares during the last quarter. Finally, TD Asset Management Inc increased its stake in Dyne Therapeutics by 103.5% in the 2nd quarter. TD Asset Management Inc now owns 152,210 shares of the company’s stock worth $5,371,000 after purchasing an additional 77,410 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Performance

Shares of DYN opened at $24.76 on Monday. Dyne Therapeutics has a fifty-two week low of $14.29 and a fifty-two week high of $47.45. The business has a 50-day moving average of $27.78 and a 200 day moving average of $34.44. The firm has a market cap of $2.52 billion, a P/E ratio of -6.96 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, research analysts predict that Dyne Therapeutics will post -3.45 earnings per share for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.